Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 34
Filtrar
Más filtros

Medicinas Complementárias
Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Microbiol Spectr ; 9(3): e0065421, 2021 12 22.
Artículo en Inglés | MEDLINE | ID: mdl-34908474

RESUMEN

The present study aimed to explore the protective effects of exogenous catalase (CAT) from microorganisms against lipopolysaccharide (LPS)-induced intestinal injury and its molecular mechanism in weaned pigs. Fifty-four weaned pigs (21 days of age) were randomly allocated to CON, LPS, and LPS+CAT groups. The pigs in CON and LPS groups were fed a basal diet, whereas the pigs in LPS+CAT group fed the basal diet with 2,000 mg/kg CAT supplementation for 35 days. On day 36, six pigs were selected from each group, and LPS and LPS+CAT groups were administered with LPS (50 µg/kg body weight). Meanwhile, CON group was injected with an equivalent amount of sterile saline. Results showed that LPS administration damaged intestinal mucosa morphology and barrier. However, CAT supplementation alleviated the deleterious effects caused by LPS challenge through enhancing intestinal antioxidant capacity which was benefited to decrease proinflammatory cytokines concentrations and suppress enterocyte apoptosis. Besides, LPS-induced gut microbiota dysbiosis was significantly shifted by CAT through decreasing mainly Streptococcus and Escherichia-Shigella. Our study suggested that dietary supplemented with 2,000 mg/kg catalase was conducive to improve intestinal development and protect against LPS-induced intestinal mucosa injury via enhancing intestinal antioxidant capacity and altering microbiota composition in weaned pigs. IMPORTANCE Exogenous CAT derived from microorganisms has been widely used in food, medicine, and other industries. Recent study also found that exogenous CAT supplementation could improve growth performance and antioxidant capacity of weaned pigs. However, it is still unknown that whether dietary exogenous CAT supplementation can provide a defense against the oxidative stress-induced intestinal damage in weaned pigs. Our current study suggested that dietary supplemented with 2,000 mg/kg CAT was conducive to improve intestinal development and protect against LPS-induced intestinal mucosa injury via enhancing intestinal antioxidant capacity and altering microbiota composition in weaned pigs. Moreover, this study will also assist in developing of CAT produced by microorganisms to attenuate various oxidative stress-induced injury or diseases.


Asunto(s)
Antioxidantes/metabolismo , Catalasa/administración & dosificación , Proteínas Fúngicas/administración & dosificación , Enfermedades Intestinales/veterinaria , Intestinos/metabolismo , Penicillium chrysogenum/enzimología , Enfermedades de los Porcinos/tratamiento farmacológico , Animales , Suplementos Dietéticos/análisis , Terapia Enzimática , Microbioma Gastrointestinal/efectos de los fármacos , Enfermedades Intestinales/tratamiento farmacológico , Enfermedades Intestinales/metabolismo , Enfermedades Intestinales/microbiología , Intestinos/efectos de los fármacos , Intestinos/lesiones , Intestinos/microbiología , Lipopolisacáridos/efectos adversos , Estrés Oxidativo/efectos de los fármacos , Penicillium chrysogenum/química , Porcinos , Enfermedades de los Porcinos/etiología , Enfermedades de los Porcinos/metabolismo , Enfermedades de los Porcinos/microbiología
2.
Vet Med Sci ; 6(3): 639-648, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-32207876

RESUMEN

In aquaculture, antibiotics are commonly used to provide protection against pathogens; however, this practice has become controversial due to increased occurrences of microbial resistance, and alternatives are needed. This study aimed to investigate the antimicrobial activity of yeast glycoprotein (YG) against Aeromonas caviae. Pathogens were isolated from liver of diseased Carassius auratus gibelio. Based on morphological and biochemical analysis, together with 16S rRNA gene sequencing, the isolated strains were identified as A. caviae and concluded as clones of a single strain and named L2. Further pathogenicity analysis revealed that A. caviae possessed ß-haemolysis, and its median lethal dose for C. gibelio was 1.33 × 106  CFU/ml. Hepatic adenylate kinase and pyruvate kinase activities of C. gibelio were inhibited post-A. caviae infection. Antimicrobial drug test suggested that A. caviae was a multidrug-resistant organism but could be inhibited by YG in vitro. Minimum inhibitory and bactericidal concentration of YG was 83.3 mg/ml and 166.7 mg/ml, respectively. Microbiota sequencing results showed that YG supplement could obviously decrease the relative abundance of Aeromonas and increase the microbial diversity. Our study revealed that A. caviae from C. gibelio was a multidrug-resistant bacteria strain, and could be significantly inhibited by YG in vivo and in vitro, thus providing important insights into ecological control and pathogenesis of A. caviae in aquaculture.


Asunto(s)
Aeromonas caviae/efectos de los fármacos , Antibacterianos/farmacología , Proteínas Fúngicas/farmacología , Glicoproteínas/farmacología , Alimentación Animal/análisis , Animales , Dieta/veterinaria , Suplementos Dietéticos/análisis , Relación Dosis-Respuesta a Droga , Farmacorresistencia Bacteriana Múltiple , Enfermedades de los Peces/prevención & control , Proteínas Fúngicas/administración & dosificación , Glicoproteínas/administración & dosificación , Carpa Dorada , Infecciones por Bacterias Gramnegativas/prevención & control , Distribución Aleatoria
3.
Biotechnol Lett ; 42(4): 557-569, 2020 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-32040674

RESUMEN

OBJECTIVE: To provide an alternative therapeutic modality for rheumatoid arthritis (RA), a novel bispecific antibody (BsAb) targeting human tumor necrosis factor α (TNF-α) and human complement component C5a was constructed. RESULTS: BsAb was expressed in Pichia pastoris and secreted into the culture medium as a functional protein. In vitro functional study demonstrated that BsAb could simultaneously bind to TNF-α and C5a and neutralize their biological actions. Furthermore, BsAb showed significant improvements in both the antigen-binding affinity and the neutralizing ability as compared to its original antibodies produced in E. coli. It was also found that TNF-α and C5a had an additive/synergistic effect on promoting the production of inflammatory cytokines and chemokines and C5a receptor (C5aR) expression in human macrophages. Compared to single inhibition of TNF-α or C5a with respective antibody, BsAb showed a superior efficacy in blocking inflammatory cytokines, chemokines, and C5aR response, as well as in lowering the C5a-mediated chemotaxis of macrophages via C5aR in vitro. CONCLUSIONS: With improved production processing and the ability to simultaneously block TNF-α and C5a action, BsAb has a great potential to be developed into a therapeutic agent and may offer a better therapeutic index for RA.


Asunto(s)
Anticuerpos Biespecíficos/administración & dosificación , Anticuerpos Biespecíficos/metabolismo , Artritis Reumatoide/tratamiento farmacológico , Pichia/crecimiento & desarrollo , Receptor de Anafilatoxina C5a/antagonistas & inhibidores , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Animales , Anticuerpos Biespecíficos/farmacología , Artritis Reumatoide/inmunología , Línea Celular , Células Cultivadas , Medios de Cultivo/química , Modelos Animales de Enfermedad , Proteínas Fúngicas/administración & dosificación , Proteínas Fúngicas/metabolismo , Proteínas Fúngicas/farmacología , Humanos , Leucocitos Mononucleares/citología , Leucocitos Mononucleares/efectos de los fármacos , Leucocitos Mononucleares/inmunología , Macrófagos/citología , Macrófagos/efectos de los fármacos , Macrófagos/inmunología , Ratones , Pichia/metabolismo
4.
J Dairy Sci ; 102(8): 6959-6970, 2019 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-31255265

RESUMEN

In this paper, we report the physicochemical and sensory properties of milk supplemented with a powder of microencapsulated lactase. The core material was lactase (ß-galactosidase), the primary coating material was medium-chain triglyceride (MCT), and the secondary (enteric) coating material was either hydroxypropyl methylcellulose phthalate (HPMCP) or shellac, comparing both against market milk as a control. The physicochemical properties of both types of microcapsules were analyzed, including the particle size, zeta potential, and in vitro release behavior. To survey the stability of the microcapsules in milk during storage, we studied the residual lactose content and pH. Furthermore, to determine the properties of milk supplemented with the microcapsules, changes in color and sensory properties were evaluated during storage. The particle sizes (volume-weighted mean; D[4,3]) of the microcapsules coated with HPMCP or shellac were 2,836 and 7,834 nm, respectively, and the zeta potential of the capsules coated with shellac was higher than the zeta potential of those coated with HPMCP. The pH levels of milk supplemented with the lactase microcapsules were similar to those of the control (unsupplemented market milk); however, for milk supplemented with HPMCP-coated microcapsules, the pH was slightly lower. The core material, lactase, was released from the microcapsules during 12-d storage, and 18.82 and 35.09% of lactose was hydrolyzed in the samples for HPMCP- and shellac-coated microcapsules, respectively. The sensory characteristics of milk containing microcapsules coated with HPMCP did not show significant differences from the control, in terms of sweetness or off-taste, until 8 d of storage. However, shellac-coated microcapsules showed significant difference in sweetness and off-taste at d 8 and 6 of storage, respectively. The color of milk containing HPMCP-coated microcapsules did not show a significant difference during storage. However, that containing shellac-coated microcapsules was somewhat higher in color values than others. In particular, it showed significance from 0 to 4 d storage in L* and C* values. In conclusion, a powder of lactase microcapsules coated with HPMCP can be suitable as a supplement for milk.


Asunto(s)
Suplementos Dietéticos , Kluyveromyces/enzimología , Lactasa/administración & dosificación , Metilcelulosa/análogos & derivados , Leche/química , Animales , Cápsulas , Fenómenos Químicos , Composición de Medicamentos/veterinaria , Proteínas Fúngicas/administración & dosificación , Hidrólisis , Lactosa/metabolismo , Metilcelulosa/química , Leche/metabolismo , Tamaño de la Partícula , Polvos , Resinas de Plantas/química , Gusto , Triglicéridos/química
5.
Fish Shellfish Immunol ; 84: 704-710, 2019 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-30359751

RESUMEN

Japanese eel (Anguilla japonica) has become a commercially important fish species all over the world. High-density aquaculture has led to congestion and contributed to bacterial infection outbreaks that have caused high mortality. Therefore a 56-days feeding trial was conducted to determine the effects of dietary Bacillus amyloliquefaciens (GB-9) and Yarrowia lipolytica lipase2 (YLL2) on growth performance, digestive enzymes activity, innate immunity and resistance to pathogens of A. japonica. Fish growth performance was significantly affected by dietary YLL2 supplementation but not by GB-9. Fish fed diets with YLL2 at 2.0 g/kg diet in combination of high and low levels of GB-9 (5.0 g/kg and 2.0 g/kg) produced the highest growth. For digestive enzyme, lipase and trypsin activities was promoted by dietary containing YLL2, while amylase activities was increased by dietary containing YLL2, GB-9 single or combination. For innate immunity, the mucus lysozyme activity, leukocytes phagocytosis activity and reactive oxygen species level of skin, peroxidase and lysozyme activity of serum were enhanced in fish fed with GB-9 compared to those in control group (p < 0.05). The highest resistance to Vibrio anguillarum and Aeromonas hydrophila was determined in fish fed with 5.0 g kg-1 GB-9 + 2.0 g/kg YLL2. This study demonstrated that GB-9 and YLL2 enhanced non-specific immune defense system of A. japonica, providing them with higher resistance to pathogens. The present results suggested that the combination of these supplements could be considered as potential biological additives for aquaculture farmed fish.


Asunto(s)
Anguilla/inmunología , Bacillus amyloliquefaciens/química , Hidrolasas de Éster Carboxílico/administración & dosificación , Enfermedades de los Peces/inmunología , Proteínas Fúngicas/administración & dosificación , Inmunidad Innata/efectos de los fármacos , Inmunidad Mucosa/efectos de los fármacos , Probióticos/farmacología , Aeromonas hydrophila/fisiología , Anguilla/crecimiento & desarrollo , Anguilla/metabolismo , Animales , Dieta/veterinaria , Suplementos Dietéticos/análisis , Relación Dosis-Respuesta a Droga , Tracto Gastrointestinal/enzimología , Infecciones por Bacterias Gramnegativas/inmunología , Infecciones por Bacterias Gramnegativas/veterinaria , Distribución Aleatoria , Vibrio/fisiología , Vibriosis/inmunología , Vibriosis/veterinaria
6.
Fish Shellfish Immunol ; 82: 250-257, 2018 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-30125703

RESUMEN

A 12-weeks feeding trial was performed to investigate the possible effects of supplementation of Hybrid sturgeon diet with Bacillus amyloliquefaciens (GB-9) and Yarrowia lipolytica lipase2 (YLL2) single or combined on immune response and growth performance of Hybrid sturgeon (Acipenser schrenkii ♂and Acipenser baeri ♀). For this aim, Hybrid sturgeons were fed with four experimental diets namely: Diet 1 (0-control), Diet 2 (5.0 g/kg GB-9), Diet 3 (4.0 g/kg YLL2), and Diet 4 (5.0 g/kg GB-9 + 4.0 g/kg YLL2), respectively. After fed with varied diets, growth performance, mucosal immune response, leukocytes immune response and serum immunological response were measured. The results indicated that supplementations of GB-9 + YLL2 resulted in a significant increase in final weight, Docosahexaenoic acid (DHA) and Eicosapentenoic acid (EPA) concentration, compared with that of control (p < 0.05). For innate immunity, the results showed that skin mucus lysozyme activity, leukocytes phagocytosis activity and reactive oxygen species level, and serum alternative complement pathway activity, peroxidase and lysozyme activity were significantly higher in supplemented groups compared to the control (p < 0.05). The highest values were recorded in fish fed both YLL2 and GB-9 with respect to the individual application. The present results suggested that the combination of these supplementation could be considered as potential feed-additives for aquaculture farmed fish.


Asunto(s)
Bacillus amyloliquefaciens/química , Hidrolasas de Éster Carboxílico/administración & dosificación , Peces/crecimiento & desarrollo , Peces/inmunología , Proteínas Fúngicas/administración & dosificación , Probióticos/farmacología , Alimentación Animal/análisis , Animales , Cruzamiento , Dieta/veterinaria , Suplementos Dietéticos/análisis , Inmunidad Innata/efectos de los fármacos , Inmunidad Mucosa/efectos de los fármacos , Distribución Aleatoria
7.
Poult Sci ; 96(11): 3960-3972, 2017 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-29050421

RESUMEN

Two broiler chicken experiments were conducted to investigate the effects of canola meal (CM) replacing soybean meal (SBM) in diets supplemented with carbohydrase and protease on performance and partitioning of energy. First, a 2 × 2 × 2 factorial arrangement of treatments was employed to evaluate: protein meals (CM vs. SBM), carbohydrase (none or 300 mg/kg), protease (none or 200 mg/kg), and their interactions. Each treatment was fed to 6 replicated pens of 16 male broilers (Ross 308) from d 10 to 35. In the second experiment, 32 broiler chicks were used in a 2 × 2 factorial arrangement to investigate CM and carbohydrase effects on energy partitioning. Birds were transferred into 16 closed-circuit calorimeter chambers (4 chambers/diet; 2 birds/chamber) to measure heat production (HP), metabolizable and net energy (NE) by gaseous exchange, and total excreta collection from d 25 to 28. There were no 3-way interactions among experimental factors for any of the performance parameters measured. Birds given CM diets consumed less feed, had lower BW, and exhibited higher FCR compared to the control birds (P < 0.01). Both enzymes, alone or in combination, improved final BW and FCR (P < 0.05). There was an interaction between carbohydrase and protease for FCR over the grower period (P < 0.01), in which the combination of the enzymes resulted in further improvement of FCR. Energy, DM, and crude protein digestibility values were higher in control birds (P < 0.05). There was an interaction of protein meal and carbohydrase for HP, respiratory quotient (P < 0.05), and NE:ME ratio of the diets (P = 0.06). Inclusion of CM without carbohydrase increased HP and decreased NE and NE:ME ratio of the diets (P < 0.05). Carbohydrase decreased HP and increased retained energy (P = 0.06) and NE and NE:ME ratio (P < 0.05). In conclusion, high CM in the diet negatively affects growth performance through reduction in feed consumption, nutrient digestibility, and NE of the diet, which could partly be restored by enzyme supplementation.


Asunto(s)
Brassica/química , Pollos/fisiología , Digestión/efectos de los fármacos , Metabolismo Energético/efectos de los fármacos , Glicósido Hidrolasas/metabolismo , Serina Proteasas/metabolismo , Actinomycetales/química , Alimentación Animal/análisis , Fenómenos Fisiológicos Nutricionales de los Animales , Animales , Aspergillus/química , Bacillus licheniformis/genética , Pollos/crecimiento & desarrollo , Dieta/veterinaria , Suplementos Dietéticos/análisis , Proteínas Fúngicas/administración & dosificación , Proteínas Fúngicas/metabolismo , Glicósido Hidrolasas/administración & dosificación , Masculino , Microorganismos Modificados Genéticamente/genética , Distribución Aleatoria , Serina Proteasas/administración & dosificación
8.
J Microbiol Immunol Infect ; 50(3): 297-306, 2017 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-26427878

RESUMEN

BACKGROUND/PURPOSE: House dust mite (HDM) is well known as one of the major indoor allergens that trigger allergic inflammation, especially asthma, and accounts for 85% of all cases. So far, asthma has been thought of as a condition of imbalance between T helper (Th)1 and Th2. Fungal immunomodulatory protein-Flammulina velutipes (FIP-fve) has been seemingly demonstrated to modulate the response to Th1 cytokine production. The aim of this study was to investigate if the oral administration of FIP-fve can inhibit HDM-induced asthma inflammation in the mouse model. METHODS: We divided the mice (female BALB/c, 4-6 weeks) into four groups: the prevention group, which consisted of mice sensitized by HDM (intraperitoneally on Day 1, Day 7, and Day 14, and intranasally on Day 14, Day 17, Day 21, Day 24, and Day 27) fed with FIP-fve from Day 1 to Day 14; the treatment group, which comprised mice that received treatment from Day 14 to Day 28; the positive control (PC, sensitized by HDM fed without FIP-fve) group; and the negative control group (NC, nonsensitized). Airway hyperresponsiveness induced by methacholine challenge was determined using whole-body barometric plethysmography. In addition, cytokines were analyzed from bronchoalveolar lavage fluid and serum. Histopathological studies and Liu's staining method in mice lungs were also performed. RESULTS: The results showed that both pre- and posttreated FIP-fve groups had significantly reduced airway hyperresponsiveness compared with the PC group after methacholine challenge. In addition, a significantly decreased level of HDM-specific immunoglobulin E in serum and decreased production of Th2 cytokines in bronchoalveolar lavage fluid and serum were observed in these two FIP-fve fed groups. Moreover, more decreased amounts of infiltrating inflammatory cells were present in the lungs of FIP-fve fed groups than those of the PC group. CONCLUSION: Oral FIP-fve had an anti-inflammatory effect on the acute phase of the airway inflammatory process induced by HDM in the mouse model and might have a potentially therapeutic role for allergic airway diseases.


Asunto(s)
Asma/tratamiento farmacológico , Flammulina/química , Proteínas Fúngicas/administración & dosificación , Factores Inmunológicos/administración & dosificación , Administración Oral , Animales , Modelos Animales de Enfermedad , Femenino , Proteínas Fúngicas/aislamiento & purificación , Histocitoquímica , Factores Inmunológicos/aislamiento & purificación , Ratones Endogámicos BALB C , Pletismografía , Pyroglyphidae/inmunología , Resultado del Tratamiento
9.
J Sci Food Agric ; 97(3): 733-742, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-27558451

RESUMEN

The global expansion in aquaculture production implies an emerging need of suitable and sustainable protein sources. Currently, the fish feed industry is dependent on high-quality protein sources of marine and plant origin. Yeast derived from processing of low-value and non-food lignocellulosic biomass is a potential sustainable source of protein in fish diets. Following enzymatic hydrolysis, the hexose and pentose sugars of lignocellulosic substrates and supplementary nutrients can be converted into protein-rich yeast biomass by fermentation. Studies have shown that yeasts such as Saccharomyces cerevisiae, Candida utilis and Kluyveromyces marxianus have favourable amino acid composition and excellent properties as protein sources in diets for fish, including carnivorous species such as Atlantic salmon and rainbow trout. Suitable downstream processing of the biomass to disrupt cell walls is required to secure high nutrient digestibility. A number of studies have shown various immunological and health benefits from feeding fish low levels of yeast and yeast-derived cell wall fractions. This review summarises current literature on the potential of yeast from lignocellulosic biomass as an alternative protein source for the aquaculture industry. It is concluded that further research and development within yeast production can be important to secure the future sustainability and economic viability of intensive aquaculture. © 2016 Society of Chemical Industry.


Asunto(s)
Alimentación Animal/análisis , Acuicultura , Peces/crecimiento & desarrollo , Abastecimiento de Alimentos , Proteínas Fúngicas/administración & dosificación , Salud Global , Levaduras/aislamiento & purificación , Aminoácidos/análisis , Alimentación Animal/economía , Animales , Acuicultura/economía , Acuicultura/tendencias , Biomasa , Conservación de los Recursos Naturales/economía , Conservación de los Recursos Naturales/tendencias , Producción de Cultivos/economía , Digestión , Fermentación , Peces/metabolismo , Abastecimiento de Alimentos/economía , Agricultura Forestal/economía , Proteínas Fúngicas/biosíntesis , Proteínas Fúngicas/química , Proteínas Fúngicas/economía , Humanos , Residuos Industriales/análisis , Residuos Industriales/economía , Lignina/química , Lignina/aislamiento & purificación , Lignina/metabolismo , Desnutrición/economía , Desnutrición/prevención & control , Ciclo del Nitrógeno , Levaduras/química , Levaduras/crecimiento & desarrollo , Levaduras/metabolismo
10.
Phytomedicine ; 23(13): 1566-1573, 2016 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-27823620

RESUMEN

BACKGROUND: Chloroquine, a lysosomal inhibitor, is used for malaria, rheumatoid arthritis, and lupus erythematosus therapy. In our previous study, FIP-gts, an immunomodulatory protein from Ganoderma tsugae, inhibited cell viability in lung cancer cells and urothelial cancer cells. Urothelial carcinoma is the most common type of bladder cancer. Cisplatin resistance is an important issue in urothelial carcinoma therapy. PURPOSE: The aim of this study is to investigate the effect of combination treatment with FIP-gts and chloroquine on cytotoxicity to resensitize the cisplatin-resistant cells. METHODS: FIP-gts and chloroquine cytotoxicity were determined by evaluating CCK-8 assay. Cell death pathways, ROS and cell cycle arrested were analysed through flow cytometry and Western blot. ShRNA targeting to autophagy-related genes were tested to evaluate their autophagic cell death for resistant urothelial cells. RESULTS: Using CCK-8 assay, chloroquine increased FIP-gts-induced cytotoxicity in parental and cisplatin-resistant urothelial cancer cell lines. On flow cytometry, chloroquine enhanced FIP-gts-mediated sub-G1 accumulation, annexin V positive signal and mitochondrial membrane potential loss. Caspase-3/PARP cascade and z-VAD-fmk were performed to prove that FIP-gts and chloroquine induced caspase-independent cell death. Using H2DCFDA staining and flow cytometry, FIP-gts and chloroquine did not induce ROS production. N-acetyl cysteine, a ROS scavenger, inhibited the cytotoxicity and LC3-II accumulation in FIP-gts and chloroquine-treated N/P cells. To elucidate the role of autophagy in caspase-independent cell death by FIP-gts and chloroquine, LC3 shRNA were used to inhibit autophagy in N/P cells. The capabilities of FIP-gts and chloroquine to induce cytotoxicity and sub-G1 phase accumulation were abolished in autophagy-defective cells. This is the first study to reveal the novel function of FIP-gts in triggering caspase-independent cell death in cisplatin-resistant urothelial cancer cells. CONCLUSION: Chloroquine enhanced FIP-gts-induced autophagy dependent caspase-independent cell death via abundant autophagosome accumulation. Combination treatment with FIP-gts and chloroquine may provide a new strategy for urothelial cancer therapy.


Asunto(s)
Autofagia/efectos de los fármacos , Cloroquina/farmacología , Cisplatino/farmacología , Proteínas Fúngicas/farmacología , Factores Inmunológicos/farmacología , Neoplasias Urológicas/tratamiento farmacológico , Clorometilcetonas de Aminoácidos/farmacología , Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Apoptosis/efectos de los fármacos , Caspasas/metabolismo , Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Cloroquina/administración & dosificación , Resistencia a Antineoplásicos/efectos de los fármacos , Proteínas Fúngicas/administración & dosificación , Ganoderma/química , Humanos , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Neoplasias Urológicas/patología
11.
Arch Anim Nutr ; 70(3): 224-38, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27032031

RESUMEN

This study was designed to assess the effectiveness of dietary cellulase (243 U/g, derived from Neocallimastix patriciarum) and a Saccharomyces cerevisiae fermentation product (yeast product) on ruminal fermentation characteristics, enteric methane (CH4) emissions and methanogenic community in growing goats. The experiment was conducted in a 5 × 5 Latin square design using five Xiangdong black wether goats. The treatments included a Control and two levels of cellulase (0.8 g and 1.6 g/kg dry matter intake (DMI), i.e. 194 U/kg and 389 U/kg DMI, respectively) crossed over with two levels (6 g or 12 g/kg DMI) of the yeast product. There were no significant differences regarding feed intake, apparent digestibility of organic matter, neutral detergent fibre and acid detergent fibre among all the treatments. In comparison with the Control, the ruminal ammonia N concentration was decreased (p = 0.001) by cellulase and yeast product addition. The activities of carboxymethylcellulase and xylanase were decreased after cellulase addition. Moreover, dietary cellulase and yeast product addition led to a significant reduction (p < 0.05) of enteric CH4 emissions although the diversity and copy numbers of methanogens among treatments were not dissimilar. The present results indicate that the combination of cellulase and yeast fermentation product can reduce the production of CH4 energy and mitigate the enteric CH4 emissions to a certain degree.


Asunto(s)
Celulasa/metabolismo , Cabras/fisiología , Metano/metabolismo , Neocallimastix/química , Saccharomyces cerevisiae/química , Alimentación Animal/análisis , Animales , Celulasa/química , Dieta/veterinaria , Suplementos Dietéticos/análisis , Fermentación , Proteínas Fúngicas/administración & dosificación , Proteínas Fúngicas/química , Microbioma Gastrointestinal/fisiología , Cabras/microbiología , Masculino , Rumen/microbiología , Rumen/fisiología
12.
Eur J Surg Oncol ; 41(6): 795-800, 2015 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-25887287

RESUMEN

BACKGROUND: The aim of the present study was to evaluate the clinical significance of protein-bound polysaccharide K (PSK) in patients with primary gastric cancer who were being treated with an oral fluoropyrimidine (S-1). METHODS: Clinical reports of 190 gastric cancer patients treated with S-1 chemotherapy, with or without PSK, at Kochi Medical School between 2007 and 2012 were investigated retrospectively to analyze survival. The neutrophil:lymphocyte ratio (NLR) was also evaluated as indicator of the immunoenhancing effect of PSK. RESULTS: Overall survival was significantly longer in patients treated with S-1 + PSK than in those given S-1 alone (hazard ratio for death, 0.608; 95% confidence interval 0.375-0.985; P = 0.041). Furthermore, there was a tendency for changes in the NLR during chemotherapy to be lower in the S-1 + PSK group than in the S-1 group, but the difference did not reach statistical significance (P = 0.054). When patients were divided into groups based on preoperative NLR (i.e. <2.5 and ≥2.5), the mean (±SEM) NLR 1 month after the beginning of chemotherapy in the NLR ≥2.5 subgroup was significantly lower in patients treated with S-1 + PSK rather than S-1 alone (1.7 ± 0.7 vs. 3.3 ± 4.1, respectively; P = 0.043). CONCLUSIONS: Immunochemotherapy using PSK improves the survival of patients with advanced gastric cancer. The NLR may be a useful biomarker for evaluating prognosis in these patients.


Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Linfocitos , Neutrófilos , Neoplasias Gástricas/tratamiento farmacológico , Adenocarcinoma/sangre , Adenocarcinoma/cirugía , Anciano , Anciano de 80 o más Años , Combinación de Medicamentos , Femenino , Proteínas Fúngicas/administración & dosificación , Proteínas Fúngicas/inmunología , Humanos , Inmunoterapia , Estimación de Kaplan-Meier , Recuento de Linfocitos , Masculino , Persona de Mediana Edad , Ácido Oxónico/administración & dosificación , Polisacáridos/administración & dosificación , Polisacáridos/inmunología , Estudios Retrospectivos , Neoplasias Gástricas/sangre , Neoplasias Gástricas/cirugía , Tasa de Supervivencia , Tegafur/administración & dosificación
13.
J Control Release ; 207: 93-100, 2015 Jun 10.
Artículo en Inglés | MEDLINE | ID: mdl-25862515

RESUMEN

Albumin fusion/conjugation (albumination) has been an effective method to prolong in vivo half-life of therapeutic proteins. However, its broader application to proteins with complex folding pathway or multi-subunit is restricted by incorrect folding, poor expression, heterogeneity, and loss of native activity of the proteins linked to albumin. We hypothesized that the site-specific conjugation of albumin to a permissive site of a target protein will expand the utilities of albumin as a therapeutic activity extender to proteins with a complex structure. We show here the genetic incorporation of a non-natural amino acid (NNAA) followed by chemoselective albumin conjugation to prolong therapeutic activity in vivo. Urate oxidase (Uox), a therapeutic enzyme for treatment of hyperuricemia, is a homotetramer with multiple surface lysines, limiting conventional approaches for albumination. Incorporation of p-azido-l-phenylalanine into two predetermined positions of Uox allowed site-specific linkage of dibenzocyclooctyne-derivatized human serum albumin (HSA) through strain-promoted azide-alkyne cycloaddition (SPAAC). The bio-orthogonality of SPAAC resulted in the production of a chemically well-defined conjugate, Uox-HSA, with a retained enzymatic activity. Uox-HSA had a half-life of 8.8 h in mice, while wild-type Uox had a half-life of 1.3 h. The AUC increased 5.5-fold (1657 vs. 303 mU/mL x h). These results clearly demonstrated that site-specific albumination led to the prolonged enzymatic activity of Uox in vivo. Site-specific albumination enabled by NNAA incorporation and orthogonal chemistry demonstrates its promise for the development of long-acting protein therapeutics with high potency and safety.


Asunto(s)
Aspergillus flavus/enzimología , Proteínas Fúngicas/biosíntesis , Albúmina Sérica/biosíntesis , Urato Oxidasa/biosíntesis , Animales , Área Bajo la Curva , Aspergillus flavus/genética , Estabilidad de Medicamentos , Estabilidad de Enzimas , Femenino , Proteínas Fúngicas/administración & dosificación , Proteínas Fúngicas/química , Proteínas Fúngicas/genética , Proteínas Fúngicas/farmacocinética , Semivida , Inyecciones Intravenosas , Ratones Endogámicos C57BL , Ingeniería de Proteínas , Proteínas Recombinantes de Fusión/biosíntesis , Albúmina Sérica/administración & dosificación , Albúmina Sérica/química , Albúmina Sérica/genética , Albúmina Sérica/farmacocinética , Albúmina Sérica Humana , Urato Oxidasa/administración & dosificación , Urato Oxidasa/química , Urato Oxidasa/genética , Urato Oxidasa/farmacocinética
14.
PLoS Negl Trop Dis ; 8(12): e3317, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25474158

RESUMEN

BACKGROUND: Paracoccin (PCN) is an N-acetylglucosamine-binding lectin from the human pathogenic fungus Paracoccidioides brasiliensis. Recombinant PCN (rPCN) induces a T helper (Th) 1 immune response when prophylactically administered to BALB/c mice, protecting them against subsequent challenge with P. brasiliensis. In this study, we investigated the therapeutic effect of rPCN in experimental paracoccidioidomycosis (PCM) and the mechanism accounting for its beneficial action. METHODOLOGY/PRINCIPAL FINDINGS: Four distinct regimens of rPCN administration were assayed to identify which was the most protective, relative to vehicle administration. In all rPCN-treated mice, pulmonary granulomas were less numerous and more compact. Moreover, fewer colony-forming units were recovered from the lungs of rPCN-treated mice. Although all therapeutic regimens of rPCN were protective, maximal efficacy was obtained with two subcutaneous injections of 0.5 µg rPCN at 3 and 10 days after infection. The rPCN treatment was also associated with higher pulmonary levels of IL-12, IFN-γ, TNF-α, nitric oxide (NO), and IL-10, without IL-4 augmentation. Encouraged by the pulmonary cytokine profile of treated mice and by the fact that in vitro rPCN-stimulated macrophages released high levels of IL-12, we investigated the interaction of rPCN with Toll-like receptors (TLRs). Using a reporter assay in transfected HEK293T cells, we verified that rPCN activated TLR2 and TLR4. The activation occurred independently of TLR2 heterodimerization with TLR1 or TLR6 and did not require the presence of the CD14 or CD36 co-receptors. The interaction between rPCN and TLR2 depended on carbohydrate recognition because it was affected by mutation of the receptor's N-glycosylation sites. The fourth TLR2 N-glycan was especially critical for the rPCN-TLR2 interaction. CONCLUSIONS/SIGNIFICANCE: Based on our results, we propose that PCN acts as a TLR agonist. PCN binds to N-glycans on TLRs, triggers regulated Th1 immunity, and exerts a therapeutic effect against P. brasiliensis infection.


Asunto(s)
Proteínas Fúngicas/administración & dosificación , Lectinas/administración & dosificación , Paracoccidioidomicosis/prevención & control , Receptores Toll-Like/inmunología , Animales , Proteínas Fúngicas/inmunología , Células HEK293 , Humanos , Lectinas/inmunología , Masculino , Ratones , Ratones Endogámicos BALB C , Paracoccidioidomicosis/tratamiento farmacológico , Paracoccidioidomicosis/inmunología , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/inmunología
15.
Biocontrol Sci ; 19(1): 51-5, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24670619

RESUMEN

Candida albicans malate dehydrogenase (Mdh1p) has been screened by previous proteome studies as a candidate for a vaccine against candidiasis. In this study, recombinant Mdh1 protein with a His-tag was produced in Escherichia coli and evaluated as an immunogenic protein against candidiasis. Mdh1p was administrated to mice by two methods subcutaneous injection and intranasal administration before challenging them with a lethal dose of C. albicans. After vaccination of Mdh1p, antibody responses were observed. To evaluate the vaccination effect of Mdh1p, survival tests were performed after 35 d. Although all control mice died within 24 d or 25 d, 100% and 80% of mice survived with subcutaneous and intranasal administration, respectively. Therefore, our results indicate that, among C. albicans antigens examined thus far, Mdh1p is currently the most effective antigen for use as a vaccine for C. albicans.


Asunto(s)
Candida albicans/enzimología , Candidiasis/prevención & control , Proteínas Fúngicas/inmunología , Vacunas Fúngicas/inmunología , Malato Deshidrogenasa/inmunología , Animales , Anticuerpos Antifúngicos/inmunología , Candida albicans/genética , Candida albicans/inmunología , Candidiasis/inmunología , Candidiasis/microbiología , Evaluación Preclínica de Medicamentos , Femenino , Proteínas Fúngicas/administración & dosificación , Proteínas Fúngicas/genética , Vacunas Fúngicas/administración & dosificación , Vacunas Fúngicas/genética , Humanos , Malato Deshidrogenasa/administración & dosificación , Malato Deshidrogenasa/genética , Ratones , Ratones Endogámicos C57BL , Vacunación
16.
Vet Q ; 33(3): 132-8, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24161027

RESUMEN

BACKGROUND: Besides the anticoccidial drug resistance problem, increasing consumer concerns about food safety and residues have propelled the quest for alternative prevention and control strategies amongst which phytotherapy has gained appeal due to a renewed interest in natural medicine. OBJECTIVE: The objective was in vivo screening of four phytochemicals/extracts and a fungal immunomodulatory protein (FIP) against an Eimeria acervulina infection in broilers. ANIMALS AND METHODS: Four phytochemicals/extracts (extract from Echinacea purpurea, betaine (Betain™), curcumin, carvacrol (two different doses)), and a recombinant FIP from Ganoderma lucidum cloned and expressed in Escherichia coli were investigated for their anticoccidial potential. The experiment was conducted in a battery cage trial with 54 cages of eight birds each. Broilers infected with E. acervulina (a low and high infection dose of 10(4) and 10(5) sporulated oocysts, respectively) and treated with the phytochemicals/extracts or the FIP were compared with broilers treated with the anticoccidial salinomycin sodium (Sacox®) and with an untreated uninfected and an untreated infected control group. Coccidiosis lesion scores, body weight gains and oocyst shedding were used as parameters. RESULTS: The results showed a coccidiosis infection dose effect on the mean coccidiosis lesion scores. The phytochemicals/extracts and the FIP failed to reduce coccidiosis lesion scores and oocyst shedding, while salinomycin efficiently controlled the E. acervulina infection and enabled significantly higher body weight gains. CONCLUSION: In conclusion, the selected phytochemicals/extracts and the FIP did not reduce the lesions of an experimentally induced E. acervulina infection.


Asunto(s)
Pollos , Coccidiosis/veterinaria , Coccidiostáticos/farmacología , Eimeria/efectos de los fármacos , Proteínas Fúngicas/farmacología , Extractos Vegetales/farmacología , Enfermedades de las Aves de Corral/tratamiento farmacológico , Animales , Betaína/administración & dosificación , Betaína/farmacología , Coccidiosis/tratamiento farmacológico , Coccidiosis/parasitología , Coccidiostáticos/administración & dosificación , Curcumina/administración & dosificación , Curcumina/farmacología , Cimenos , Relación Dosis-Respuesta a Droga , Echinacea/química , Escherichia coli/genética , Proteínas Fúngicas/administración & dosificación , Proteínas Fúngicas/genética , Factores Inmunológicos/administración & dosificación , Factores Inmunológicos/farmacología , Masculino , Monoterpenos/administración & dosificación , Monoterpenos/farmacología , Extractos Vegetales/administración & dosificación , Enfermedades de las Aves de Corral/parasitología , Piranos/administración & dosificación , Piranos/farmacología , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/genética , Proteínas Recombinantes/farmacología , Reishi/química , Reishi/genética , Organismos Libres de Patógenos Específicos
17.
Immunopharmacol Immunotoxicol ; 35(3): 426-33, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23656432

RESUMEN

The aim of the study is to investigate the effect of recombinant Ganoderma lucidum immunoregulatory protein (rLZ-8) on mouse models of cyclophosphamide-induced leukopenia, which we have established with both single-phase and multi-phase administration methods. Treatment with rLZ-8 had a strong effect on both models of cyclophosphamide-induced leukopenia. In particular, it increased the number of neutrophils, lymphocytes and monocytes. rLZ-8 treatment also increased the percentage of CD4(+) T cells and the levels of secreted IL-3 and IL-4, which contributed to the cyclophosphamide-induced immune dysfunction and immune system imbalance. In conclusion, rLZ-8 treatment benefitted mice with cyclophosphamide-induced leukopenia by improving overall immune function and by specifically increasing the number of white blood cells.


Asunto(s)
Antineoplásicos Alquilantes/efectos adversos , Ciclofosfamida/efectos adversos , Proteínas Fúngicas/uso terapéutico , Leucopenia/tratamiento farmacológico , Reishi/química , Animales , Citocinas/inmunología , Modelos Animales de Enfermedad , Ensayo de Inmunoadsorción Enzimática , Citometría de Flujo , Proteínas Fúngicas/administración & dosificación , Proteínas Fúngicas/genética , Recuento de Leucocitos , Leucocitos/citología , Leucopenia/sangre , Leucopenia/inducido químicamente , Leucopenia/inmunología , Masculino , Ratones , Ratones Endogámicos BALB C
18.
Indian J Med Res ; 138(6): 969-76, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24521644

RESUMEN

BACKGROUND & OBJECTIVES: Destruxin A, destruxin B and destruxin E isolated from entomopathogenic fungus Metarhizium anisopliae showed a strong suppressive effect on the replication of hepatitis B virus (HBV) in human hepatoma cells. In this study, the anti-HBV effects of the crude destruxins extracted from M. anisopliae var. dcjhyium were detected both in vitro and in vivo. METHODS: HepG2.2.15 cells were cultured to observe the inhibitory effects of the crude destruxins on the gene expression and replication of HBV by radioimmunoassay detection and real-time quantitative PCR. In vivo, duck HBV (DHBV)-infected ducks were treated with the crude destruxins at 2.0, 4.0, 6.0 µg/kg once a day for 15 days, DHBV DNA was examined by real-time quantitative PCR. RESULTS: The crude destruxins suppressed the replication of HBV-DNA and the production of HBsAg and HBeAg with IC 50 of about 1.2 and 1.4 µg/ml. Transcript of viral mRNA was significantly suppressed by the crude destruxins in HepG2.2.15 cells. In vivo, the duck serum DHBV-DNA levels were markedly reduced in the group of the crude destruxins. INTERPRETATION & CONCLUSIONS: The crude destruxins inhibited the gene expression and replication of HBV both in vitro and in vivo, and their anti-HBV effect was stronger than that with destruxin B. Our results indicate that the crude destruxins from M.anisopliae var. dcjhyium may be potential antivirus agents. Further studies need to be done to confirm these findings.


Asunto(s)
Depsipéptidos/administración & dosificación , Proteínas Fúngicas/administración & dosificación , Regulación Viral de la Expresión Génica/efectos de los fármacos , Virus de la Hepatitis B/efectos de los fármacos , Animales , ADN Viral/efectos de los fármacos , Depsipéptidos/aislamiento & purificación , Patos/virología , Proteínas Fúngicas/aislamiento & purificación , Células Hep G2 , Hepatitis B/tratamiento farmacológico , Hepatitis B/virología , Virus de la Hepatitis B del Pato/efectos de los fármacos , Virus de la Hepatitis B/genética , Humanos , Metarhizium , Extractos Vegetales/química , Replicación Viral
19.
Int J Clin Oncol ; 15(2): 145-52, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20229169

RESUMEN

BACKGROUND: A recent report showed that oral adjuvant immunochemotherapy with protein-bound polysaccharide K (PSK) and tegafur/uracil (UFT) for stage II and III colorectal cancer improves overall survival compared with UFT alone. PSK has been supposed to improve survival through immunological mechanisms such as induction of cytokines, regulation of Th1/Th2 balance, and inhibition of immunosuppressive molecules. METHODS: We investigated the mechanisms by which PSK influences immunological parameters such as Th1 cells (IFN-gamma-positive CD4(+) T cells), Th2 cells (IL-4-positive CD4(+) T cells), Th1/Th2 ratio, NKT cells (CD56(+) T cells and CD57(+) T cells), NK cells, and CD25(+)CD4(+) T cells in stage III gastric cancer patients. Patients were randomly assigned to receive either 3 g PSK plus 300 mg UFT (PSK group) or 300 mg UFT alone (control) orally each day for at least 1 year following their operation. RESULTS: Twenty-one registered patients with stage III gastric cancer were analyzed. The 3-year overall survival was 62.2% in the PSK group (n = 10) and 12.5% in the control group (n = 11) (P = 0.038). Before operation, there were no significant differences in the proportions of Th1 cells, Th2 cells, Th1/Th2 ratio, CD56(+) T cells, CD57(+) T cells, NK cells, and CD4(+)CD25(+) T cells between PSK and control groups. However, after operation, CD57(+) T cells decreased significantly in the PSK group compared to the control (P = 0.0486). When all patients were analyzed, patients with increased proportion (>18%) of CD57(+) T cells showed worse survival than those with lower (< or = 18%) CD57(+) T cells (3-year survival, 25.0 and 45.7%, respectively; P = 0.046), consistent with our previous report that high CD57(+) is an indicator of poor prognosis in patients with advanced gastric cancer. However, in the group treated with PSK + UFT, 3-year survival of CD57-high patients was as great as that of CD57-low patients (66.7 and 51.4%, respectively; P = 0.67). CONCLUSION: The present findings suggest that PSK improves overall survival of stage III gastric cancer patients partly by inhibiting CD57(+) T cells, a proven poor prognostic factor in advanced gastric cancer.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Antígenos CD57/análisis , Neoplasias Gástricas/tratamiento farmacológico , Subgrupos de Linfocitos T/efectos de los fármacos , Anciano , Quimioterapia Adyuvante , Distribución de Chi-Cuadrado , Combinación de Medicamentos , Femenino , Proteínas Fúngicas/administración & dosificación , Gastrectomía , Humanos , Estimación de Kaplan-Meier , Escisión del Ganglio Linfático , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Polisacáridos/administración & dosificación , Neoplasias Gástricas/inmunología , Neoplasias Gástricas/mortalidad , Neoplasias Gástricas/patología , Neoplasias Gástricas/cirugía , Subgrupos de Linfocitos T/inmunología , Tegafur/administración & dosificación , Factores de Tiempo , Resultado del Tratamiento , Uracilo/administración & dosificación
20.
Rev Alerg Mex ; 57(4): 107-11, 2010.
Artículo en Español | MEDLINE | ID: mdl-21255522

RESUMEN

BACKGROUND: In Mexico, the way allergen immunotherapy is performed has remained without changes for many years. Here we present the modifications that have been performed in the General Hospital of Mexico to make immunotherapy more effective. OBJECTIVE: To show the changes implemented to make immunotherapy faster and more effective by changing the volume of allergy vaccines from 5 or 10 mL to 3 mL, and the theoretical and practical support for the change. MATERIAL AND METHOD: The amount of protein delivered in each immunotherapy shot was computed to show how they change along the treatment. Results for schedules for 3, 5 and 10 mL were compared. RESULTS: Results showed serial rises and falls in protein amount injected every time a new vaccine flask starts to be used. However, in the case for 3 mL vaccines schedules, those changes are less pronounced. CONCLUSIONS: Due to these results we suggest a schedule of immunotherapy with 3 mL vaccines that allow getting the maintenance doses in a shorter time and at lower cost.


Asunto(s)
Alérgenos/uso terapéutico , Alergia e Inmunología , Desensibilización Inmunológica/métodos , Departamentos de Hospitales , Hospitales Generales , Alérgenos/administración & dosificación , Protocolos Clínicos , Desensibilización Inmunológica/economía , Desensibilización Inmunológica/normas , Relación Dosis-Respuesta a Droga , Proteínas Fúngicas/administración & dosificación , Proteínas Fúngicas/análisis , Proteínas Fúngicas/uso terapéutico , Humanos , Proteínas de Insectos/administración & dosificación , Proteínas de Insectos/análisis , Proteínas de Insectos/uso terapéutico , México , Proteínas de Plantas/administración & dosificación , Proteínas de Plantas/análisis , Proteínas de Plantas/uso terapéutico , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA